SIREN : 301763405
CEVA SANTE ANIMALE is a French company founded 44 years ago, specialized in the sector Fabrication de préparations pharmaceutiques. Based in LIBOURNE (33500), this company of category ETI shows in 2023 a revenue of 812.3 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 812 289 000 € | 759 639 000 € | 756 515 000 € | 663 173 000 € | 622 404 000 € | 576 005 000 € | 533 085 000 € | 439 474 000 € | 373 066 000 € | 309 255 000 € |
| Net income | 70 158 000 € | 71 327 000 € | 94 496 000 € | 33 054 000 € | 23 982 000 € | 72 430 000 € | 63 259 000 € | 36 091 000 € | 19 215 000 € | 31 860 000 € |
| EBITDA | 178 283 000 € | 151 857 000 € | 186 262 000 € | 132 395 000 € | 88 284 000 € | 126 608 000 € | 986 926 000 € | 60 096 000 € | 712 671 000 € | 36 147 000 € |
| Net margin | 8.6% | 9.4% | 12.5% | 5.0% | 3.9% | 12.6% | 11.9% | 8.2% | 5.2% | 10.3% |
In 2023, CEVA SANTE ANIMALE achieves revenue of 812.3 M€. Over the period 2014-2023, the company shows strong growth with a CAGR (compound annual growth rate) of +11.3%. Vs 2022: +7%. After deducting consumption (285.4 M€), gross margin stands at 526.9 M€, i.e. a rate of 65%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 178.3 M€, representing 21.9% of revenue. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 70.2 M€, i.e. 8.6% of revenue. This profit can be retained or distributed to shareholders.
812 289 000 €
526 882 000 €
178 283 000 €
131 534 000 €
70 158 000 €
21.9%
The debt ratio (= Financial debt / Equity x 100) stands at 172%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 27%. The balance between equity and debt is satisfactory. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 7.5 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high. Cash flow represents 19.6% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
171.538%
27.484%
19.574%
7.454
59.5%
In 2023, the debt ratio of CEVA SANTE ANIMALE (171.54) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.
In 2023, the financial autonomy of CEVA SANTE ANIMALE (27.5%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2023, the repayment capacity of CEVA SANTE ANIMALE (7.45) ranks in the top 25% of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A long duration may signal heavy debt relative to repayment capacity.
The liquidity ratio (= Current assets / Current liabilities) stands at 116.57. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 75.8x. Operating income very largely covers interest expenses: high safety margin.
116.569
75.843
In 2023, the liquidity ratio of CEVA SANTE ANIMALE (116.57) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2023, the interest coverage of CEVA SANTE ANIMALE (75.8x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 88 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 85 days. The company must finance 3 days of gap between collections and payments. Inventory turnover is 84 days (= Average inventory / Cost of goods x 360). Overall, WCR represents 26 days of revenue, i.e. 58.1 M€ to permanently finance. Notable WCR improvement over the period (-20%), freeing up cash.
58 103 032 €
88 j
85 j
84 j
26 j
Indicative estimate only : the number of comparable transactions in this sector is limited (27 transactions). This range of 13 997 872€ to 43 023 987€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 27 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare CEVA SANTE ANIMALE with other companies in the same sector:
Voir toutes les statistiques du secteur Fabrication de préparations pharmaceutiques
The revenue of CEVA SANTE ANIMALE in 2023 is 812.3 M€.
Yes, CEVA SANTE ANIMALE generated a net profit of 70.2 M€ in 2023.
The headquarters of CEVA SANTE ANIMALE is located in LIBOURNE (33500), in the department Gironde.
The tax return of CEVA SANTE ANIMALE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
CEVA SANTE ANIMALE operates in the sector Fabrication de préparations pharmaceutiques (NAF code 21.20Z). See the 'Sector positioning' section above to compare the company with its competitors.